Stay updated with breaking news from One Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
One Bio entered the market last month on a mission to end inflammatory disease and decimate food waste by making odorless, colorless and tasteless fiber from salvaged agricultural byproducts.
With a U.S. biotech identified as One Bio, Jiangsu Hengrui Pharmaceutical Co. Ltd. has inked an out-licensing deal potentially worth $1.05 billion for its asthma and chronic sinusitis-targeting drug, SHR-1905. The latest deal gives One Bio exclusive rights to develop, produce and commercialize SHR-1905 worldwide, excluding the greater China territory.
With a U.S. biotech identified as One Bio, Jiangsu Hengrui Pharmaceutical Co. Ltd. has inked an out-licensing deal potentially worth $1.05 billion for its asthma and chronic sinusitis-targeting drug, SHR-1905. The latest deal gives One Bio exclusive rights to develop, produce and commercialize SHR-1905 worldwide, excluding the greater China territory.
Stock prices of multiple cancer drug companies soared Monday following the release of positive clinical trial results for their therapies at an ongoing industry conference in Chicago.
Stock prices of multiple cancer drug companies soared Monday following the release of positive clinical trial results for their therapies at an ongoing industry conference in Chicago.